Sign In
Buy PBYI
$8.04
+0.380 (+4.96%)
At Close: Jun 23, 2026
LOS ANGELES--(BUSINESS WIRE)--The FDA cleared Puma Biotechnology's IND for Alisertib in HER2-negative, hormone receptor-positive metastatic breast cancer.
PBYI vs. RGEN: Which Stock Is the Better Value Option?
12:46pm, Monday, 04'th Mar 2024
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Puma Biotech (PBYI) and Repligen (RGEN). But which of these two companies is the best op
Why Puma Biotech (PBYI) is a Top Value Stock for the Long-Term
10:46am, Friday, 01'st Mar 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates
10:41am, Friday, 01'st Mar 2024
Puma Biotechnology's (PBYI) fourth-quarter 2024 earnings and revenues fall shy of estimates. Stock declines.
Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript
08:39pm, Thursday, 29'th Feb 2024
Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
04:05pm, Thursday, 29'th Feb 2024
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology released it's fourth quarter and full year 2023 earnings and will host a conference call to discuss operating results and outlook.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06:30pm, Tuesday, 27'th Feb 2024
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 26, 2024, the Compensation Committee of Puma's Board of Directors approve
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
12:56pm, Tuesday, 27'th Feb 2024
On Puma Biotechnology's (PBYI) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen's 44th Annual Health Care Conference
04:10pm, Thursday, 22'nd Feb 2024
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO and President Alan Auerbach will participate in a Breast & Lung Cancer panel on 3/6/24 at TD Cowen's Health Care Conference .
Puma Biotech (PBYI) Is Up 23.01% in One Week: What You Should Know
01:01pm, Wednesday, 21'st Feb 2024
Does Puma Biotech (PBYI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
04:10pm, Thursday, 15'th Feb 2024
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PT on Feb. 29 to discuss its fourth quarter and full year 2023 earnings results.
5 Biotech Stocks to Consider for Your Portfolio in 2024
10:00am, Tuesday, 13'th Feb 2024
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR,
Strength Seen in Puma Biotech (PBYI): Can Its 10.0% Jump Turn into More Strength?
05:11am, Tuesday, 13'th Feb 2024
Puma Biotech (PBYI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term
PBYI vs. AMGN: Which Stock Should Value Investors Buy Now?
12:40pm, Friday, 09'th Feb 2024
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Puma Biotech (PBYI) and Amgen (AMGN). But which of these two stocks offers value investors a better
3 small-cap biotechs with potential breakthroughs in 2024
10:16am, Tuesday, 06'th Feb 2024
There's a reason that many biotech investors prefer to stick with large-cap stocks. Investing in small-cap biotech stocks is not for risk-averse investors.
